A case series of a luteolin formulation (neuroprotek®) in children with autism spectrum disorders

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 2, 2012, Pages 317-323

  Theoharides, T C ^a   Asadi, S ^a,b   Panagiotidou, S ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

Autism; Brain; Flavonoids; Inflammation; Luteolin; Mast cells; Treatment

Indexed keywords

LUTEOLIN; NEUROPROTEK; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG; OLIVE OIL;

ABSORPTION; ADOLESCENT; ALLERGY; ATTENTION; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG FORMULATION; DRUG TOLERABILITY; ENCEPHALITIS; FEMALE; HUMAN; HUMAN CELL; MALE; NEUROPROTECTION; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SOCIAL INTERACTION; SPEECH; ABSENCE OF SIDE EFFECTS; CASE STUDY; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; INFLAMMATION; MAST CELL; SPEECH ARTICULATION;

EID: 84863708123     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500201     Document Type: Review

References (40)

1. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120(5): 1183-215. (Pubitemid 350085561)
2. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006; 160(8):825-30. (Pubitemid 44199242)
3. Broadstock M, Doughty C, Eggleston M. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism 2007; 11(4):335-48. (Pubitemid 47244226)
4. Rogers SJ, Vismara LA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol 2008; 37(1):8-38.
5. King BH, Hollander E, Sikich L, et al. Lack of efficacy of Citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry 2009; 66(6):583-90.
6. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011; 127(5):e1312-21.
7. Bersani G, Gherardelli S, Clemente R, et al. Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol 2005; 25(4):372-5. (Pubitemid 41060259)
8. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008; 454(7203):445-54.
9. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta 2010; 1822(1):21-33.
10. Theoharides TC, Angelidou A, Alysandratos KD, et al. Mast cell activation and autism. Biochim Biophys Acta 2012; 1822(1):34-41.
11. Saggini A, Tripodi D, Maccauro G, et al. Tumor necrosis factor-alpha and mast cells. Eur J Inflamm 2011; 9(1):17-22.
12. Theoharides TC, Doyle R. Autism, gut-blood-brain barrier and mast cells. J Clin Psychopharmacol 2008; 28(5):479-83.
13. Angelidou A, Francis K, Vasiadi M, et al. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation 2010; 7:48.
14. Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res 2003; 59(1):241-9. (Pubitemid 36776390)
15. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006; 80(1):1-15. (Pubitemid 44841805)
16. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57(1):67-81. (Pubitemid 40053317)
17. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007; 36(6):361-5. (Pubitemid 46873913)
18. Li X, Chauhan A, Sheikh AM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009; 207(1-2):111-6.
19. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27(40):10695-702. (Pubitemid 47535869)
20. Magalhaes ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA, Deazevedo LC. Immune allergic response in Asperger syndrome. J Neuroimmunol 2009; 216(1-2):108-12.
21. Angelidou A, Alysandratos KD, Asadi S, et al. Brief Report: "Allergic Symptoms" in children with Autism Spectrum Disorders. More than meets the eye? J Autism Dev Disord 2011; 41:1579-85.
22. Jyonouchi H. Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. Expert Rev Clin Immunol 2010; 6(3):397-411.
23. Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol 2009; 22(4):859-65.
24. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128:344-50.
25. Middleton E, Jr., Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52:673-751.
26. Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005; 145:934-44. (Pubitemid 41129015)
27. Yao Y, Walsh WJ, McGinnis WR, Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006; 63(8):1161-4. (Pubitemid 44232325)
28. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 2008; 105(21):7534-9. (Pubitemid 351830053)
29. Sharma V, Mishra M, Ghosh S, et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007; 73(1-3):55-63. (Pubitemid 46710246)
30. Dirscherl K, Karlstetter M, Ebert S, et al. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 2010; 7(1):3.
31. Kempuraj D, Tagen M, Iliopoulou BP, et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008; 155:1076-84.
32. Parker-Athill E, Luo D, Bailey A, et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009; 217(1-2):20-27.
33. Asadi S, Zhang B, Weng Z. et al. Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol 2010; 23(4):1015-20.
34. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000; 30:501-8. (Pubitemid 30253188)
35. Haleagrahara N, Radhakrishnan A, Lee N, Kumar P. Flavonoid quercetin protects against swimming stress-induced changes in oxidative biomarkers in the hypothalamus of rats. Eur J Pharmacol 2009; 621(1-3):46-52.
36. Kumar A, Goyal R. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food 2008; 11(3):469-73.
37. Shimoi K, Okada H, Furugori M, et al. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett 1998; 438(3):220-4. (Pubitemid 28529277)
38. Harwood M, nielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45(11):2179-205. (Pubitemid 47451573)
39. Kawanishi S, Oikawa S, Murata M. Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal 2005; 7(11-12):1728-39. (Pubitemid 41768004)
40. De BD, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010; 23(2):417-22.